Canada - English - Health Canada

auro pharma inc - aripiprazole - tablet - 15mg - aripiprazole 15mg - atypical antipsychotics

Canada - English - Health Canada

pharmascience inc - aripiprazole - tablet - 5mg - aripiprazole 5mg - atypical antipsychotics

Canada - English - Health Canada

pharmascience inc - aripiprazole - tablet - 15mg - aripiprazole 15mg - atypical antipsychotics

Canada - English - Health Canada

apotex inc - aripiprazole - tablet - 5mg - aripiprazole 5mg - atypical antipsychotics

Canada - English - Health Canada

apotex inc - aripiprazole - tablet - 15mg - aripiprazole 15mg - atypical antipsychotics

Canada - English - Health Canada

teva canada limited - aripiprazole - tablet - 5mg - aripiprazole 5mg - atypical antipsychotics

Canada - English - Health Canada

teva canada limited - aripiprazole - tablet - 15mg - aripiprazole 15mg - atypical antipsychotics

United States - English - NLM (National Library of Medicine)

ajanta pharma usa inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole oral tablets are indicated for the treatment of: - schizophrenia - irritability associated with autistic disorder - treatment of tourette’s disorder aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including aripiprazole, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery (see clinical considerations) . overall av

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 1 mg in 1 ml - aripiprazole oral solution is indicated for the treatment of: - schizophrenia [see clinical studies (14.1)] - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies (14.2)] - adjunctive treatment of major depressive disorder [see clinical studies (14.3)] - irritability associated with autistic disorder [see clinical studies (14.4)] - treatment of tourette’s disorder [see clinical studies (14.5)] aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalh

United States - English - NLM (National Library of Medicine)

apotex corp. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 1 mg in 1 ml - aripiprazole oral solution is indicated for the treatment of: - schizophrenia [see clinical studies (14.1)]   - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies (14.2)]  - adjunctive treatment of major depressive disorder [see  clinical studies (14.3)]  - irritability associated with autistic disorder [see clinical studies (14.4)]  - treatment of tourette’s disorder [see clinical studies (14.5)] aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions (6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://wom